Recombinant erythropoietin long-acting - Shandong Kexing Bioproducts

Drug Profile

Recombinant erythropoietin long-acting - Shandong Kexing Bioproducts

Latest Information Update: 07 Feb 2014

Price : $50

At a glance

  • Originator Shandong Kexing Bioproducts Co; Unknown
  • Developer Shandong Kexing Bioproducts Co
  • Class Antianaemics; Recombinant erythropoietins; Recombinant fusion proteins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase Unknown Anaemia

Most Recent Events

  • 01 Jan 2014 Investigation in Anaemia in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top